AP NEWS

Global Epilepsy Drugs Market 2018-2022 with Eisai, GlaxoSmithKline, Novartis & Pfizer Dominating - ResearchAndMarkets.com

October 2, 2018

DUBLIN--(BUSINESS WIRE)--Oct 2, 2018--The “Global Epilepsy Drugs Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

The Global Epilepsy Drugs Market to grow at a CAGR of 7.19% during the period 2018-2022.

Global Epilepsy Drugs Market 2018-2022 has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

According to the report, one driver influencing this market is the advances in understanding of epilepsy pathology. Several programs have been launched worldwide to develop effective and safe drugs for the treatment of seizures in epileptic patients which is expected to boost the growth of the epilepsy drugs market in the next few years.

One trend affecting this market is the increasing costs of epilepsy management. The direct costs associated with the treatment of epilepsy include costs of hospitalization, outpatient treatment, diagnostic workup, nursing care, and parents’ copayments is increasing.

Further, the report states that one challenge affecting this market is the low safety profile of AEDs. The global epilepsy drugs market has several clinical and non-clinical unmet needs, such as low safety profile of AEDs especially among women.

Key vendors:

Eisai GlaxoSmithKline Novartis Pfizer

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

Market ecosystem Market characteristics Market segmentation analysis

PART 05: PIPELINE ANALYSIS

Unmet needs of available AEDs Pipeline drugs for epilepsy

PART 06: MARKET SIZING

PART 07: MARKET SIZING 2017-2022

PART 08: FIVE FORCES ANALYSIS

Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition

PART 09: MARKET SEGMENTATION BY DRUG ACTIVITY SPECTRUM

Segmentation by drug activity spectrum Comparison by drug activity spectrum Narrow spectrum drugs Broad spectrum drugs Market opportunity by drug activity spectrum

PART 10: MARKET SEGMENTATION BY ETIOLOGY

Segmentation by etiology

PART 11: MARKET SEGMENTATION BY AGE OF ONSET

PART 12: CUSTOMER LANDSCAPE

PART 13: REGIONAL LANDSCAPE

Geographical segmentation Regional comparison Market opportunity

PART 14: DECISION FRAMEWORK

PART 15: DRIVERS AND CHALLENGES

PART 16: MARKET TRENDS

Increase in epilepsy management costs Use of immunotherapy and immunomodulators Use of genetics as therapeutics and diagnostic modality Research in precision healthcare infrastructure

PART 17: VENDOR LANDSCAPE

Landscape disruption

PART 18: VENDOR ANALYSIS

Vendors covered Vendor classification Market positioning of vendors

For more information about this report visit https://www.researchandmarkets.com/research/h8gbh2/global_epilepsy?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181002005865/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 10/02/2018 12:33 PM/DISC: 10/02/2018 12:33 PM

http://www.businesswire.com/news/home/20181002005865/en

AP RADIO
Update hourly